Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite...

|About: Supernus Pharmaceuticals, Inc. (SUPN)|By:, SA News Editor

Supernus Pharmaceuticals (SUPN) jumps at the open but gives back the entire gain, despite receiving approval from the FDA for its epilepsy treatment, Oxtellar XR, a once-daily extended release formulation of oxcarbazepine. The FDA also granted a waiver for the pediatric study requirement for ages birth to one month and a deferral for submission of post-marketing assessments for children one month to 6 years of age.